Ranolazine and Linagliptin Interaction
Drug interaction information between Ranolazine and Linagliptin.
Ranolazine and Linagliptin have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Ranolazine and Linagliptin. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.
How They Interact
Ranolazine stops your kidneys from getting rid of metformin properly. This can lead to a buildup of the drug, which increases the risk of a serious side effect called lactic acidosis.
FDA Label Information
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Ranolazine Also Interacts With
- Ketoconazole major
- Carbamazepine major
- Clarithromycin major
- Rifampin major
- Phenytoin major
Linagliptin Also Interacts With
- Metformin moderate
- Dolutegravir moderate
- Cimetidine moderate
- Topiramate minor
- Rifampin minor
Frequently Asked Questions
What SPL severity band is on file for Ranolazine + Linagliptin?
Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.
Which drug in this pair has the larger labeled-interaction portfolio?
Ranolazine has 31 labeled pairs on file vs Linagliptin's 9. In the moderate band specifically: Ranolazine has 7 (also Empagliflozin, Empagliflozin/Linagliptin, Ertugliflozin, Lovastatin); Linagliptin has 4 (also Metformin, Dolutegravir, Cimetidine).
What mechanism field is on file for Ranolazine and Linagliptin?
Ranolazine stops your kidneys from getting rid of metformin properly. This can lead to a buildup of the drug, which increases the risk of a serious side effect called lactic acidosis.
Ranolazine carries more major-labeled pairs than Linagliptin
SPL source-record counts only. This page's band is moderate · classes on file: Ranolazine (Late Sodium Current Inhibitor (Antianginal)); Linagliptin (DPP-4 Inhibitor).
Ranolazine has 12 major-labeled pairs vs Linagliptin's 0. This page itself is in the moderate band, not the major band.
12 major · 7 moderate · 12 minor · 31 total
- Other moderate peers for Ranolazine
- Empagliflozin
- Empagliflozin/Linagliptin
- Ertugliflozin
- Lovastatin
0 major · 4 moderate · 5 minor · 9 total
- Other moderate peers for Linagliptin
- Metformin
- Dolutegravir
- Cimetidine
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.
Read our methodology - how this data is sourced, computed, and verified.